Trial Profile

A Phase 2B investigator lead study using psychedelics psilocybin and lysergic acid diethylamide ("LSD") to treat Parkinson's Disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Dec 2020 New trial record
02 Dec 2020 According to a Silo Pharma media release, Dr. Kim Kuypers will serve as Investigator Sponsor for the Phase 2B study. The company expects to share additional information regarding protocol, ethics submission and initiation of the study as the information becomes available.
02 Dec 2020 According to a Silo Pharma media release, the company has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson's disease and to understand its mechanism of action.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com